Opiant Pharmaceuticals (OPNT) Posts Quarterly Earnings Results
Opiant Pharmaceuticals (NASDAQ:OPNT) issued its earnings results on Monday. The technology company reported ($2.77) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.19) by ($1.58), Bloomberg Earnings reports. Opiant Pharmaceuticals had a return on equity of 278.86% and a net margin of 35.68%.
Opiant Pharmaceuticals (NASDAQ OPNT) traded up $0.80 during trading on Tuesday, reaching $31.36. The company’s stock had a trading volume of 31,300 shares, compared to its average volume of 35,379. Opiant Pharmaceuticals has a 52 week low of $5.00 and a 52 week high of $51.90. The stock has a market capitalization of $62.28, a PE ratio of 10.57 and a beta of -2.33.
OPNT has been the subject of several research reports. ValuEngine upgraded Opiant Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, September 6th. TheStreet upgraded Opiant Pharmaceuticals from a “c+” rating to a “b” rating in a research note on Monday, October 16th.
About Opiant Pharmaceuticals
Opiant Pharmaceuticals, Inc, formerly Lightlake Therapeutics, Inc, is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA).
Receive News & Stock Ratings for Opiant Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.